Benchmark International Successfully Facilitated the Transaction Between Real Regulatory Limited and Transcrip Partners LLP

Benchmark International is pleased to announce the acquisition of Dublin-based Real Regulatory by private equity-backed tranScrip.

Real Regulatory is a consultancy firm specialising in European regulatory affairs, quality systems and compliance for products including medicines, medical devices, and drug device combinations. Headquartered in Dublin, the company also has offices in Cambridgeshire and Malta.

Founder and managing director, Karen Real, who has more than 35 years’ experience in the pharmaceutical industry, will remain with the business moving forward.

tranScrip is a fast-growing contract drug development organisation which supports the development and lifecycle of medicines. It is backed by private equity firm, Palatine, and the deal is the first acquisition made by the company since securing Palatine’s investment in 2021 via its dedicated Impact Fund.

The strategic acquisition significantly expands tranScrip’s regulatory affairs capabilities, strengthening its ability to provide comprehensive support to its customers.

Ms Real commented: "I am delighted to be joining tranScrip and having got to know their people over the last few months, I know there is a brilliant business and cultural fit between the two companies, which I am sure will be highly beneficial to the Real Regulatory team and of course to both organisations' clients.

"As Real Regulatory enters its third decade in business I feel incredibly energised by the opportunities this combination with tranScrip will deliver, and I can’t wait to get working on helping to drive the growth."

Dr Marcin Mankowski, managing partner at tranScrip, said: "We are excited to have completed this highly strategic and important acquisition, the first since the Palatine Impact investment last year.

"We see major synergies between tranScrip and real regulatory teams. Regulatory affairs is a fundamental element of drug development from pre-clinical stages to product registration and expanding our offering in this key area is critical for our continuous growth."

Tristan Craddock, impact partner at Palatine, added: "We are delighted to support this transformational acquisition, which adds a skilled and experienced regulatory capability to tranScrip's differentiated offering, and also an international presence with offices in Dublin and Malta, which can be a further platform for growth moving forward.

"Since our investment 14 months ago we have seen significant organic growth and we look forward to this momentum continuing following this important and value-enhancing deal."

Share This Post